|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 107.81 USD | -0.14% |
|
+2.00% | -13.95% |
| 08-07 | US FDA to hold advisory meeting to review Grail's multi-cancer test | RE |
| 08-06 | Becton Dickinson Lifts Full-Year Profit Outlook as Third-Quarter Results Top Views | MT |
Company Valuation: Abbott Laboratories
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 241,365 | 191,427 | 191,088 | 196,184 | 217,859 | 186,553 | - | - |
| Change | - | -20.69% | -0.18% | 2.67% | 11.05% | -14.37% | - | - |
| Enterprise Value (EV) 1 | 249,166 | 198,318 | 198,871 | 202,693 | 222,266 | 210,718 | 207,969 | 204,168 |
| Change | - | -20.41% | 0.28% | 1.92% | 9.66% | -5.2% | -1.3% | -1.83% |
| P/E | 35.7x | 28.1x | 33.8x | 14.8x | 33.7x | 30.9x | 23.8x | 21.2x |
| PBR | 6.93x | 5.2x | 4.94x | 4.11x | 4.18x | 3.88x | 3.71x | 3.5x |
| PEG | - | -36.9x | -2x | 0x | -0.7x | -4.89x | 0.8x | 1.7x |
| Capitalization / Revenue | 5.6x | 4.39x | 4.76x | 4.68x | 4.91x | 3.71x | 3.41x | 3.19x |
| EV / Revenue | 5.78x | 4.54x | 4.96x | 4.83x | 5.01x | 4.19x | 3.81x | 3.5x |
| EV / EBITDA | 19.4x | 15.9x | 19.5x | 19.1x | 18.9x | 16.2x | 14.4x | 12.9x |
| EV / EBIT | 22x | 17.7x | 22.3x | 21.8x | 21.6x | 18x | 16x | 14.3x |
| EV / FCF | 28.8x | 25.4x | 39.3x | 31.9x | 30.1x | 26.6x | 22.2x | 20x |
| FCF Yield | 3.47% | 3.94% | 2.54% | 3.13% | 3.33% | 3.76% | 4.5% | 5% |
| Dividend per Share 2 | 1.82 | 1.92 | 2.08 | 2.24 | 2.4 | 2.57 | 2.72 | 2.842 |
| Rate of return | 1.29% | 1.75% | 1.89% | 1.98% | 1.92% | 2.38% | 2.52% | 2.64% |
| EPS 2 | 3.94 | 3.91 | 3.26 | 7.64 | 3.72 | 3.485 | 4.529 | 5.082 |
| Distribution rate | 46.2% | 49.1% | 63.8% | 29.3% | 64.5% | 73.7% | 60.1% | 55.9% |
| Net sales 1 | 43,075 | 43,653 | 40,109 | 41,950 | 44,328 | 50,304 | 54,649 | 58,413 |
| EBITDA 1 | 12,815 | 12,485 | 10,188 | 10,635 | 11,735 | 12,993 | 14,491 | 15,876 |
| EBIT 1 | 11,324 | 11,231 | 8,911 | 9,295 | 10,301 | 11,721 | 13,023 | 14,315 |
| Net income 1 | 7,071 | 6,933 | 5,723 | 13,402 | 6,524 | 6,231 | 7,935 | 8,865 |
| Net Debt 1 | 7,801 | 6,891 | 7,783 | 6,509 | 4,407 | 24,166 | 21,416 | 17,615 |
| Reference price 2 | 140.74 | 109.79 | 110.07 | 113.11 | 125.29 | 107.81 | 107.81 | 107.81 |
| Nbr of stocks (in thousands) | 1,714,968 | 1,743,574 | 1,736,059 | 1,734,455 | 1,738,834 | 1,730,383 | - | - |
| Announcement Date | 26/1/22 | 25/1/23 | 24/1/24 | 22/1/25 | 22/1/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 30.94x | 4.19x | 16.22x | 2.38% | 187B | |
| 19.75x | 3.44x | 12.1x | 3.41% | 112B | |
| 17.52x | 0.2x | 12.83x | 0.74% | 61.15B | |
| 31.31x | 7.81x | 19.88x | 1.27% | 54.39B | |
| 34.29x | 3.31x | 11.26x | 2.22% | 48.17B | |
| 33.97x | 5.97x | 18.74x | -.--% | 31.98B | |
| 41.84x | 1.3x | 11.77x | 0.16% | 30.91B | |
| 41.29x | 7.23x | 25.96x | 0.25% | 24.92B | |
| 25.57x | 3.88x | 13.52x | 1.12% | 23.15B | |
| 19.22x | 2.85x | 10.68x | 1.52% | 22.2B | |
| Average | 29.57x | 4.02x | 15.30x | 1.31% | 59.5B | |
| Weighted average by Cap. | 28.28x | 3.91x | 15.03x | 1.88% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- ABT Stock
- Valuation Abbott Laboratories
Select your edition
All financial news and data tailored to specific country editions
